iRhythm Technologies reported Q4 revenues of $208.9 million, up 27.1% year-on-year and exceeding analysts' expectations by 3.4%. The cardiac monitoring device maker also beat earnings per share estimates, delivering the strongest analyst beat and highest full-year guidance raise among patient monitoring companies. Despite the strong results, iRhythm's shares have fallen 25.7% since reporting, currently trading at $118.09. The decline suggests investor expectations exceeded Wall Street's published projections. The patient monitoring sector overall reported solid Q4 results, with the four tracked companies beating revenue consensus estimates by 1.9% on average. However, next quarter's revenue guidance came in 1.8% below expectations, and share prices have declined an average of 10.5% following earnings announcements.

iRhythm Holdings has appointed Jason Patten to its Board of Directors, effective 12 March 2026. Patten currently serves as Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group, where he leads corporate strategy, strategic partnerships and innovation functions. The appointment comes as iRhythm, a digital healthcare company specialising in disease detection and prevention, seeks to expand from episodic detection to proactive, integrated care. Chairman Abhi Talwalkar said Patten's experience leading strategy at one of the world's largest healthcare organisations will support the company's growth across primary care, AI capabilities and multiple markets. Patten previously held positions including Chief Operating Officer at OptumHealth and worked in financial services at MoneyGram International and Carlson Marketing Group.

iRhythm (IRTC) CMO receives 15,060 RSU shares, sells 7,804 to cover taxes. Filing Impact (Very High) Filing Sentiment (Negative) Rhea-AI Filing summary. iRhythm Holdings executive Minang Turakhia, Chief Medical/Scientific Officer and EVP Advanced Technology, reported a mix of equity award and related share sale. On February 24, 2026, he acquired 15,060 shares of common stock at $0.00 per share through the vesting of performance RSUs granted on February 27, 2023, after the compensation committee determined the performance conditions were met. On February 25, 2026, he sold 7,804 shares at an average price of $135.4189 per share to cover tax withholding and remittance obligations tied to this vesting. Following these transactions, he directly held 48,899 shares of iRhythm common stock. 02/26/2026 - 05:56 PM SEC Form 4 Faq. What insider transactions did Minang Turakhia report for iRhythm Holdings (IRTC)? Minang Turakhia reported a performance-based equity award and a related share sale. He acquired 15,060 iRhythm shares via vested performance RSUs, then sold 7,804 shares to satisfy tax withholding, leaving him with 48,899 directly held common shares. How many iRhythm (IRTC) shares did Minang Turakhia acquire in the latest Form 4? He acquired 15,060 iRhythm shares at $0.00 per share. The shares came from performance RSUs granted on February 27, 2023, which vested after the board's compensation committee determined the performance conditions had been met. Why did Minang Turakhia sell iRhythm (IRTC) shares in this Form 4 filing? He sold 7,804 iRhythm shares to cover tax withholding and remittance obligations. The sale followed the vesting of performance RSUs and was executed at an average price of $135.4189 per share, according to the footnote disclosure. At what price were Minang Turakhia's iRhythm (IRTC) shares sold? The 7,804 iRhythm shares were sold at an average price of $135.4189 per share. This transaction was reported as an open-market sale and was undertaken to satisfy tax obligations associated with the RSU vesting. How many iRhythm Holdings (IRTC) shares does Minang Turakhia own after these transactions? After the reported award and tax-related sale, Minang Turakhia directly holds 48,899 shares of iRhythm common stock. This post-transaction balance reflects both the 15,060-share RSU vesting and the 7,804-share sale for tax withholding. What type of equity award did Minang Turakhia receive from iRhythm (IRTC)? He received shares upon vesting of performance Restricted Stock Units (RSUs). The compensation committee determined that performance conditions for RSUs granted on February 27, 2023, were met, resulting in the issuance of 15,060 common shares at no purchase price.